MetaVia Reports Additional Top-Line Results From The MAD Part 2 Of Its Phase 1 Study Of DA-1726, A Novel 3:1 Ratio GLP-1 And Glucagon Dual Receptor Agonist To Treat Obesity; No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate Or QTcF Measurements Of Subjects Receiving Up To 32mg Of DA-1726 At 4-Weeks; Additional Cohorts Being Added to Determine Maximum Tolerated Dose

A Dose-Dependent Response in Body Weight Reduction Was Observed Between 8 mg and 32 mg Doses

Change in BMI and Body Weight Adjusted for Height In the Treatment Groups, Showed a Significant Difference Compared to Placebo, Indicating Potentially Greater Efficacy with Increasing Dosage and Longer Duration of Use

No Drug-Induced Cardiovascular Effects Were Observed In Heart Rate or QTcF Measurements of Subjects Receiving up to 32 mg of DA-1726 at 4-Weeks

Additional Cohorts Being Added to Determine Maximum Tolerated Dose

CAMBRIDGE, Mass., April 22, 2025 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today reported additional top-line results from the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), further demonstrating its potential as a best-in-class obesity drug.

In the 28-day, 36-subject MAD portion of the study, a clear dose-responsive trend in body weight (BW) reduction was observed across the 8 mg to 32 mg range, indicating potentially greater efficacy at higher doses and longer duration of use. Additionally, body mass index (BMI), which shows body weight adjusted for height, showed a difference between the treatment group and the placebo (PBO) group, which was even more pronounced, further supporting the dose-dependent effect of the drug on weight-related outcomes. Of note, DA-1726 did not show any clinically significant increases in heart rate (HR) or QTcF changes up to 32 mg at 4 weeks of administration.

As previously reported, with no titration, DA-1726, with its novel 3:1 ratio between GLP-1R and GCGR at the 32 mg dose, demonstrated compelling maximum weight loss of -6.3% and mean weight loss of -4.3% at Day 26 (p=0.0005), while showing a strong signal of GLP-1R efficacy with maximum lowering of fasted glucose of -18 mg/dL and mean lowering of -5.3 mg/dL at Day 26, and maximum waist circumference reduction of 3.9 inches and mean reduction of 1.6 inches, indicating a strong signal of glucagon efficacy at Day 33.